Sanofi is halting the phase 3 MOBILIZE trial evaluating riliprubart for chronic inflammatory demyelinating polyneuropathy due to lack of efficacy.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026. Sanofi today announced that the riliprubart MOBILIZE phase 3 ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments -- intravenous immunoglobulin (IVIG), steroids, and plasma exchange -- are ...
(MENAFN- GetNews) The Chronic Inflammatory Demyelinating Polyneuropathy market is expected to grow steadily across the 7MM during the forecast period (2026–2036), driven by increasing disease ...
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy: Paris Thursday, June 11, 2026, 14:00 Hrs [IST] Sanofi, an R&D ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results